Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: A randomized clinical trial

Journal of Andrology

Volumn 26, Issue 3, 2005, Pages 405-413

  Anawalt, Bradley D ^a,b,c   Amory, John K ^a   Herbst, Karen L ^b   Coviello, Andrea D ^a   Page, Stephanie T ^a   Bremner, William J ^a   Matsumoto, Alvin M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c VA Puget Sound S 111 CHF ^*  (United States)

Author keywords

Azoospermia; Contraception; Free testosterone; Gonadotropins; Oligoazoospermia; Oligospermia

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE ENANTATE;

ADULT; ARTICLE; AZOOSPERMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPERMATOGENESIS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; FOLLICLE STIMULATING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEVONORGESTREL; LIPIDS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; SPERMATOGENESIS; TESTOSTERONE; WEIGHT GAIN;

EID: 18244379028     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.04135     Document Type: Article

References (31)

1. Ahsan R, Sufi SB, Cekan S. Laboratory Method Manual for the Radioimmunoassay of Levonorgestrel, Norethisterone, Norethisterone and Medroxyprogesterone Acetate. London: World Health Organization Collaborating Centre for Research and Reference Services in the Immunoassay for Hormones in Human Reproduction; 1988.
2. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134:663-694.
3. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999;20: 407-414.
4. Anderson RA, Baird DT. Male contraception. Endocrine Rev. 2002;23:735-762.
5. Anderson RA, Kinniburgh D, Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting contraception. J Clin Endocrinol Metab. 2002a;87:3640-3649.
6. Anderson RA, Van Der Spuy ZM, Dada OA, Tregoning SK, Zinn PM, Adenjii OA, Fakoya TA, Smith KB, Baird DT. Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod. 2002b;17:2869-2877.
7. Audet MC, Moreau M, Kotun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA. 2001;285:2347-2354.
8. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996;81:757-762.
9. Boonstra H, Duran V, Northington Gamble V, Blumenthal P, Dominguez L, Pies C. The "Boom or Bust Phenomenon": the hopes, dreams and broken promises of the contraceptive revolution. Contraception. 2000; 61:9-25.
10. Bremner WJ, Matsumoto AM, Sussman AM, Paulsen CA. Follicle-stimulating hormone and human spermatogenesis. J Clin Invest. 1981;68: 1044-1052.
11. Buchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre H, Nieschlag E. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab. 1999;84:1244-1249.
12. Gao E, Lin C, Gui Y, Li L, He C. Inhibiting effects of Sino-implant plus testosterone undecanoate on spermatogenesis in Chinese men. Reprod Contracep. 1999;10:98-105.
13. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87:3562-3572.
14. Gordon DL, Moore DL, Thorslund T, Paulsen CA. The determination of size and concentration of human sperm with an electronic particle counter. J Lab Clin Med. 1965;65:506-512.
15. Gu Y-Q, Wang X-H, Xu D, Peng L, Cheng L-F, Huang M-K, Huang Z-J, Zhang G-Y. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003;88:562-568.
16. Heller CG, Laidlaw WM, Harvey HT, Nelson WO. Effects of progestational compounds on the reproductive processes of the human male. Ann NY Acad Sci. 1958;71:649-665.
17. Kamischke A, Heuermann T, Krüger K, von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002;87:530-539.
18. Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E. Im testosterone undecanoate with- or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol. 2000;53:43-52.
19. Liu ST, Gui YL, Lin CH, He CH. Hormonal contraception in Chinese men: variations in suppression of spermatogenesis with injectable testosterone undecanoate and levonorgestrel implants. Asian J Androl. 2004;6:41-46.
20. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab. 2004;89: 142-149.
21. Meriggiola MC, Farley TMM, Mbizvo MT. A review of androgen-progestin regimens for male contraception. J Androl. 2003a;24:466-482.
22. Meriggiola MC, Costantino A, Cerpolini S, et al. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab. 2003b;88:5818-5826.
23. Salter AM, Brindley DN. The biochemistry of lipoproteins. J Inherit Metab Dis. 1988;11(suppl 1):4-17.
24. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
25. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. 2003;88:4659-4667.
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
27. Warnick GR. Enzymatic methods for the quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101-123.
28. 2+ precipitation procedure for quantification of high-density lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
29. World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th ed. Cambridge, United Kingdom: Cambridge University Press; 1999.
30. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336:955-959.
31. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65: 821-829.